Roche

Founded in 1896 and headquartered in Basel, Switzerland, Roche has developed into a leading healthcare company with two core business segments: Pharmaceuticals and Diagnostics. The Pharmaceuticals division is focused on advancing science to improve people's lives, with a portfolio that includes treatments for diseases such as cancer, immune disorders, infectious diseases, ophthalmological conditions, and disorders of the central nervous system. Key brands in this segment include Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for a variety of cancers, Rituxan/MabThera (rituximab) for conditions like non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as rheumatoid arthritis, Tecentriq (atezolizumab) used in immunotherapy for certain cancers, and Hemlibra (emicizumab) designed for treating hemophilia A. In the Diagnostics division, Roche Diagnostics offers an extensive array of tests and diagnostic systems that are integral in the early detection, prevention, diagnosis, and monitoring of diseases. Notable products include the Accu-Chek line for diabetes management—which provides blood glucose meters and lancing devices—and the Cobas line, which encompasses a variety of instruments and assays for automated diagnostic testing. Roche's products and services are available in over 100 countries, with the United States, Europe, and emerging markets such as China and Brazil being especially significant. The company's diversified global presence allows it to deliver cutting-edge healthcare solutions to patients around the world. (Powered by AI)